Scilex is distributing roughly 10.7 million Semnur shares to its common stockholders — out of the approximately 186 million Semnur shares it currently holds. That math matters: Scilex retains the overwhelming majority of Semnur equity after this dividend, meaning the spinout is less a divestiture than a deliberate attempt to create a second public vehicle around a single asset, SP-102 (SEMDEXA), while keeping the parent’s strategic grip intact.
The structure is a 1-for-1 share dividend with a June 1, 2026 record date, payment due within 60 days after that. SEMDEXA is a dexamethasone viscous gel for epidural injection in lumbosacral radicular pain — a Phase 3-complete, Fast Track asset that Scilex has been sitting on for years without a commercial launch. Separating it into a standalone OTC-traded entity (Semnur already trades under SMNR) theoretically lets management raise capital, attract partners, or pursue a licensing deal without the noise of Scilex’s commercial pain portfolio cluttering the story. In practice, it also gives Scilex shareholders a direct stake in the upside if SEMDEXA ever gets to an NDA submission, independent of how ZTlido, ELYXYB, or Gloperba perform.
The strategic logic is straightforward but the execution risk is real. Semnur is a single-asset, pre-revenue company trading on OTC markets — a combination that historically produces thin liquidity and limited institutional interest. The Board explicitly reserved the right to revoke or reschedule the dividend based on solvency analysis, a standard carve-out that nonetheless signals awareness of financial fragility. Scilex itself carries a commercial portfolio generating revenue but has faced persistent cash pressure, and spinning out a late-stage asset before monetizing it is a gamble that the capital markets will assign Semnur meaningful standalone value rather than simply discounting it as a stranded subsidiary.
The single number to watch after the June 1 record date is Semnur’s share price on OTC markets relative to the implied per-share value of its SEMDEXA NDA filing costs. If the stock can’t sustain a price that reflects credible development capital, the dividend creates the appearance of shareholder value without the substance — and Scilex’s core investors will notice.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
